Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind Phase IIa Study to Demonstrate the Contribution of MPL® to Tyrosine Adsorbed Birch + Hazel + Alder Pollen Allergoid (Tree MATA) With a Single-Blind Portion to Evaluate the Residual Allergenicity in Skin Test in Volunteers Allergic to Birch and Hazel and Alder Pollen

NCT00118625 is registered in ClinicalTrials.gov with Allergy Therapeutics as lead sponsor.

NCT NCT00118625
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00118625 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind Phase IIa Study to Demonstrate the Contribution of MPL® to Tyrosine Adsorbed Birch + Hazel + Alder Pollen Allergoid (Tree MATA) With a Single-Blind Portion to Evaluate the Residual Allergenicity in Skin Test in Volunteers Allergic to Birch and Hazel and Alder Pollen
Lead sponsor
Allergy Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2005
Completion date
September 30, 2005
Enrollment
40
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type i hypersensitivity